ArticleBMC complementary medicine and therapies2026
Antiplasmodial activity, phytochemical analysis and in silico study of the leaf extract of Chenopodium opulifolium Koch & Ziz used in Uganda.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The plant Chenopodium opulifolium is traditionally consumed as a food and for treating ailments. Despite its use in Uganda for treating malaria, there are no scientific studies on its phytochemicals and biological potential to ascertain its folkloric claims. In this study, bioassay (antiplasmodial activity) – guided fractionation, isolation and identification of the phytoconstituents of the leaves of C. opulifolium were carried out. The identified compounds were further investigated via in silico docking to propose the mechanism of action of the extracts.The leaves were extracted sequentially via maceration with n-hexane (HEX), dichloromethane (DCM), ethyl acetate (EtOAc), methanol (MeOH), and water. The most active MeOH and DCM extracts were fractionated via chromatography and the compounds were identified via 1D and 2D NMR, FTIR, and GC-MS techniques. The extracts and isolated compounds were tested against the P. falciparum 3D7 strain and clinical field isolates KOM_234 and KDH_204 via a fluorescence-based SYBR Green 1 assay technique. Docking was performed in the active and nucleoside binding sites of the plasmodial lactate dehydrogenase PfLDH.The five extracts showed activity against the P. falciparum 3D7 strain. The MeOH and DCM extracts were the most active with IC50 values of 0.1177 and 1.189 µg/mL respectively. In P. falciparum clinical field isolates KOM_234 and KDH_204, the MeOH extract had IC50 values of 5.30 µg/mL and 5.06 µg/mL respectively whereas allantoin from the MeOH extract had an IC50 value of 2.29 µg/mL and 10.94 µg/mL respectively. Among the identified and isolated compounds 2-myristynoyl pantetheine showed the best binding affinity (-8.3674) for plasmodial dehydrogenase (chloroquine = -6.3451). The antiplasmodial activities of the extract and the identified compounds of C. opulifolium leaves rationalize the traditional use of the plant in malaria therapy. The activity of the extracts can be attributed to the collective constituents principally 2-myristynoyl pantetheine which binds to PfLDH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.